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Purpose: The purpose of this study is to compare the dosimetry of electron beam (EB) plans and three-dimensional helical 
tomotherapy (3DHT) plans for the patients with left-sided breast cancer, who underwent breast conserving surgery.
Materials and Methods: We selected total of 15 patients based on the location of tumor, as following subsite: subareolar, 
upper outer, upper inner, lower lateral, and lower medial quadrants. The clinical target volume (CTV) was defined as the area of 
architectural distortion surrounded by surgical clip plus 1 cm margin. The conformity index (CI), homogeneity index (HI), quality 
of coverage (QC) and dose-volume parameters for the CTV, and organ at risk (OAR) were calculated. The following treatment 
techniques were assessed: single conformal EB plans; 3DHT plans with directional block of left anterior descending artery (LAD); 
and 3DHT plans with complete block of LAD.
Results: 3DHT plans, regardless of type of LAD block, showed significantly better CI, HI, and QC for the CTVs, compared with the EB 
plans. However, 3DHT plans showed increase in the V1Gy at skin, left lung, and left breast. In terms of LAD, 3DHT plans with complete 
block of LAD showed extremely low dose, while dose increase in other OARs were observed, when compared with other plans. EB 
plans showed the worst conformity at upper outer quadrants of tumor bed site.
Conclusion: 3DHT plans offer more favorable dose distributions to LAD, as well as improved target coverage in comparison with 
EB plans.
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Introduction
The current standard treatment for early breast cancer is 
breast-conserving surgery, followed by whole-breast irradiation 
and tumor-bed boost irradiation [1]. The benefit of the 
additional tumor bed boost, which has been shown to decrease 
local recurrence rates, has been supported by numbers of 
randomized studies [2-4]. The single-field electron beam (EB) 
plan has been commonly used to deliver a tumor bed boost 
with a characteristic sharp dose drop-off beyond the target 
volume. Because of the unsatisfactory target coverage of EB 
plan in some cases, tumor bed boosting with a photon beam 
was studied and has shown superior target coverage than 
EB plan [5,6]. On the other hand, photon boost have been 
discouraged because of excess doses to normal tissues such 
as lungs and heart [7]. Particularly, it is important of efforts to 
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reduce dose to left anterior descending coronary artery (LAD) 
because clinical data showed that radiation exposure of the 
heart during radiotherapy (RT) for breast cancer increases the 
rate of ischemic heart disease [8].
Modern TomoTherapy machine (Accuray Inc., Sunnyvale, 
CA, USA) provides various types of radiation delivery [9]. Users 
can select three-dimensional conformal radiotherapy (3D-CRT) 
by direct or helical beam as well as intensity-modulated 
radiotherapy (IMRT) depending on size, site, and type of tumor. 
We speculate that three-dimensional helical tomotherapy 
(3DHT) might be a favorable method for boost RT to overcome 
poor target coverage of EB plans and immoderate irradiation 
of normal tissues in photon plans. Therefore, we investigated 
the usefulness of 3DHT plans for boost RT by examining the 
dosimetric benefit of target coverage and reducing LAD dose.
Materials and Methods
1. Patient selection
To find the dosimetric differences according to tumor site 
including subareolar, upper inner, upper outer, lower medial, 
and lower lateral quadrants, we selected 3 patients for each 
group. Total of 15 patients who received adjuvant RT were 
identified from June 2010 to June 2011. Included criteria were 
as follows: 1) patients with stage I/IIA left-sided breast cancer; 
2) patient who had received definitive RT following the breast 
conserving surgery; and 3) patient who had surgical clips at 
tumor bed. 
2. Target volume delineation
Anatomic information from the computed tomography (CT) 
scan was used to define the volumes at risk and normal 
structures. The tumor bed was defined as the area of 
architectural distortion combined with the location of surgical 
clips. The clinical target volume (CTV) was delineated with a 
1 cm margin from the tumor bed, excluding the pectoralis 
muscles, chest wall, and a 5-mm depth beneath the skin. EB 
plans were designed by block margin with 1 cm margin from 
CTV because of beam penumbra and block edge effects. 
Organ at risk (OAR) included left breast, left lung, right 
breast, right lung, skin, and LAD. We delineated breast 
boundary according to the caudal edge of the sternoclavicular 
junction as cranial border, the intermammary sulcus as caudal 
border, the major pectoralis muscle as dorsal border, the 
axillary vessels as lateral border and the ipsilateral edge of 
sternum as medial border [10]. The skin was defined to be 5 
mm thick from surface of body. The contouring of the LAD was 
attempted on each CT image using the heart atlas proposed by 
Feng et al. [11].
3. Treatment planning
EB and 3DHT plans for boost RT were compared in each case. 
The EB plans used a single electron field with a central axis 
perpendicular to the CTV. In order for the CTV to be covered 
by the 90% isodose line, we selected one of electron energy 
among 6, 9, and 12 MeV depending on the depth of the CTV. 
We did not apply the bolus for EB plans because most patients 
had deep-seated CTV. The overall goal was to deliver 10 Gy 
to the CTV at 2 Gy per fraction. We performed the EB plans 
using a radiation planning program (Pinnacle3 v7.8c; Philips 
Heathcare, Andover, MA, USA). 3DHT plans were generated 
using the TomoTherapy planning system (Accuray Inc.). 
We used helical tomotherapy which is a radiation delivery 
modality that delivers a modulated fan beam using a 6-MV 
linear accelerator mounted on a ring gantry that rotates 
around patient through the gantry bore. A jaw of 2.5 cm width 
was used for all plans. 3DHT beam angles were automatically 
selected for delivery of the prescribed dose in target. And 
3DHT plans have two constraint options against contour: 
directional block and complete block. Directional block avoids 
the direct beamlet, while permitting exit beamlet. On the 
other hand, complete block does not allow entry nor exit of 
beamlet. These plans are different from IMRT. IMRT plans in 
TomoTherapy planning system should have various importance 
and weighted penalties according to constraints of OARs, 
whereas 3DHT plans can select type of block option only, as we 
mentioned above. TomoTherapy provided two 3D-CRT mode 
as well as IMRT. Users can select direct beam or helical beam 
into 3D-CRT mode depending on target. Among them, we used 
helical beam in 3D-CRT mode of TomoTherapy.
We created three artificial structures applied to directional 
block to protect OARs: block 1 for contralateral breast; block 
2 for ipsilateral lung; and block 3 for minimizing irradiated 
dose on other OARs (i.e., ipsilateral breast, skin). Block 1 was 
created at mid-sternum below skin surface in coverage of CTV 
at 5 mm thickness. The block 2 and 3 were made each slice by 
parallel planes of 4 cm distance from CTV. These blocks were 
schematic contouring for easier judgment of block effect. 
And we planned constraint of LAD for minimizing LAD dose in 
3DHT plans. We compared 3DHT plans using directional block 
with complete block of LAD (Fig. 1). A prescription dose of 10 
Gy in 5 fractions was used for each plan with the optimization 
goal of delivering the prescription dose to 90% of the CTV.
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4. Dosimetric analysis
The EB and two 3DHT plans for three patients according to 
each tumor site were compared via dose-volume histograms 
(DVH). Target coverage was assessed by comparing the 
homogeneity index (HI) and conformity index (CI) of the plan. 
The HI was defined as the ratio of the dose received by 5% 
volume of the CTV to the dose received by 95% of CTV (i.e., 
HI = D5% / D95%). The CI was defined as the ratio between the 
volume receiving at least 95% of the prescribed dose and 
the volume of the CTV (i.e., CI = V95% / CTV). For comparing of 
target coverage quality, quality control (QC) was defined by the 
ratio between the irradiated minimum dose and the prescribed 
dose for the CTV (i.e., QC = Dmin / D). 
OAR sparing was evaluated by comparing the mean dose 
as well as the dose-volume parameters. A set of appropriate 
V-values such as V1Gy, V3Gy, and V8Gy (relative volumes receiving 
≥1, ≥3, or ≥8 Gy of the prescribed dose, respectively) were also 
calculated. All plans were normalized to deliver 10 Gy within 
the 95% isodose line after completing RT for the purpose of 
dosimetric analysis.
5. Statistical analysis
One-way analysis of variance test was used to compare 
dosimetric differences among plans. All statistical tests were 
two-sided, and were performed using SPSS software program 
ver. 20.0 (IBM, Armonk, NY, USA). When comparing the 
data series, the mean values were confronted in all cases, a 
significance level of p < 0.05 was considered to be a significant 
difference.
Results
1. Target coverage
The mean CTV volume for all patients was 59.27 cm3 (range, 
23.71 to 89.30 cm3). In 3DHT plans, treatment time was 168 
± 54 seconds and monitor unit (MU) was 2,468 ± 763 MU. 
Meanwhile, EB plans showed 26 ± 12 seconds in treatment 
time and 227 ± 38 MU in MU. As shown in Table 1, the 
CTV coverage of both 3DHT plans with directional block or 
complete block of LAD was superior to that of EB plans. The 
3DHT plans provided superior CI, HI, QC, Dmean, and V95% for 
the CTVs, compared to the EB plans. EB plans had less target 
coverage compared to 3DHT plans but had no overdose 
to prescribed dose. On the other hand, 3DHT plans led to 
consistently higher (V107%), especially with the complete block 
of LAD.
A B C
Fig. 1. Isodose distribution in axial planes. (A) Electron beam plan. (B) Helical tomotherapy plan with directional block of left anterior 
descending coronary artery. (C) Helical tomotherapy plan with complete block of left anterior descending coronary artery. The black 
arrow indicates the left anterior descending coronary artery.
Table 1. Target coverage
Index Electron (E) HT-direction (D) HT-complete (C) p-value (ANOVA)
CI
HI
QC
Dmean (Gy)
V95%
V107%
0.92 ± 0.15
1.18 ± 0.79
0.59 ± 0.15
8.80 ± 0.37
92.73 ± 15.68
0
0.99 ± 0.01
0.99 ± 0.25
0.89 ± 0.21
10.23 ± 0.06
99.54 ± 0.27
 1.53 ± 2.43
0.98 ± 0.01
1.10 ± 0.04
0.83 ± 0.12
10.35 ± 0.12
98.68 ± 1.19
 11.04 ± 13.64
E vs. D (0.01); E vs. C (0.01); D vs. C (NS)
E vs. D (NS); E vs. C (0.02); D vs. C (NS)
E vs. D (<0.01); E vs. C (<0.01); D vs. C (0.04)
E vs. D (<0.01); E vs. C (<0.01); D vs. C (NS)
E vs. D (<0.01); E vs. C (<0.01); D vs. C (NS)
E vs. D (<0.01); E vs. C (<0.01); D vs. C (0.03)
Values are presented as mean ± standard deviation.
HT-direction, helical tomotherapy with directional block of LAD; HT-complete, helical tomotherapy with complete block of LAD; CI, con-
formity index; NS, not statistically significant; HI, homogeneity index; QC, quality of coverage; Dmean, mean dose; V95%, volume receiving 
≥95% of prescribed dose; V107%, volume receiving ≥107% of prescribed dose; LAD, left anterior descending coronary artery.
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Fig. 2. Target coverage according to quadrant of tumor site. CI, conformity index; HI, homogeneity index; QC, quality of coverage; HT (D), 
helical tomotherapy with directional block of left anterior descending coronary artery; HT (C), helical tomotherapy with complete block 
of left anterior descending coronary artery.
Table 2. Doses to organs at risk (n = 15)
Electron (E) HT-direction (D) HT-complete (C) p-value (ANOVA)
Skin
   Dmean (Gy)
   D1% (Gy)
   D50% (Gy)
   V1Gy (%)
LAD
   Dmean (Gy)
   D1% (Gy)
   V1Gy (%)
   V3Gy (%)
Left lung
   Dmean (Gy)
   D1% (Gy)
   V3Gy (%)
Right lung
   Dmean (Gy)
   D1% (Gy)
   V3Gy (%)
Left breast
   Dmean (Gy)
   D1% (Gy)
   D50% (Gy)
   V1Gy (%)
Right breast
   Dmean (Gy)
   D1% (Gy)
   D50% (Gy)
   V1Gy (%)
 
0.24 ± 0.08
8.38 ± 0.47
0.31 ± 1.09
4.79 ± 0.99
 
1.68 ± 1.44
 3.70 ± 2.71
44.28 ± 33.14
22.12 ± 23.64
 
0.55 ± 0.29
5.56 ± 1.73
5.69 ± 3.24
 
0
0
0
 
1.94 ± 0.58
9.30 ± 0.28
0.23 ± 0.15
24.28 ± 13.14
 
0
0
0
0
 
0.89 ± 0.18
8.71 ± 1.33
0.13 ± 0.07
19.05 ± 3.15
 
2.13 ± 1.24
4.04 ± 2.35
72.54 ± 28.48
26.20 ± 26.10
 
0.79 ± 0.18
5.95 ± 1.41
5.13 ± 2.26
 
0.25 ± 0.12
0.92 ± 0.41
0
 
3.72 ± 1.17
10.43 ± 0.08
3.05 ± 1.03
35.54 ± 18.48
 
0.30 ± 0.13
0.98 ± 0.46
0.25 ± 0.13
2.21 ± 3.60
 
0.90 ± 0.18
8.78 ± 1.48
0.11 ± 0.06
19.37 ± 3.06
 
0.50 ± 0.25
1.14 ± 0.58
9.56 ± 13.3
0
 
0.73 ± 0.19
5.37 ± 1.39
4.62 ± 2.20
 
0.21 ± 0.10
0.87 ± 3.49
0.03 ± 0.13
 
4.11 ± 0.80
10.74 ± 0.36
3.27 ± 1.14
38.36 ± 13.35
 
0.27 ± 0.16
0.95 ± 0.58
0.23 ± 0.17
3.55 ± 6.02
 
E vs. D (<0.01); E vs. C (<0.01); D vs. C (NS)
E vs. D (0.01); E vs. C (0.01); D vs. C (NS)
E vs. D (<0.01); E vs. C (<0.01); D vs. C (0.02)
E vs. D (<0.01); E vs. C (<0.01); D vs. C (NS)
 
E vs. D (<0.01); E vs. C (<0.01); D vs. C (0.01)
E vs. D (<0.01); E vs. C (<0.01); D vs. C (0.01)
E vs. D (NS); E vs. C (<0.01); D vs. C (0.01)
E vs. D (NS); E vs. C (<0.01); D vs. C (<0.01)
 
E vs. D (0.01); E vs. C (0.02); D vs. C (0.04)
E vs. D (0.04); E vs. C (NS); D vs. C (0.02)
E vs. D (0.01); E vs. C (0.01); D vs. C (0.01)
 
E vs. D (<0.01); E vs. C (<0.01); D vs. C (NS)
E vs. D (<0.01); E vs. C (<0.01); D vs. C (NS)
E vs. D (NS); E vs. C (<0.01); D vs. C (<0.01)
 
E vs. D (<0.01); E vs. C (<0.01); D vs. C (0.02)
E vs. D (<0.01); E vs. C (<0.01); D vs. C (NS)
E vs. D (<0.01); E vs. C (<0.01); D vs. C (0.02)
E vs. D (0.01); E vs. C (0.02); D vs. C (NS)
 
E vs. D (<0.01); E vs. C (<0.01); D vs. C (NS)
E vs. D (<0.01); E vs. C (<0.01); D vs. C (NS)
E vs. D (<0.01); E vs. C (<0.01); D vs. C (NS)
E vs. D (<0.01); E vs. C (<0.01); D vs. C (NS)
Values are presented as mean ± standard deviation.
HT-direction, helical tomotherapy with directional block of LAD; HT-complete, helical tomotherapy with complete block of LAD; Dmean, 
mean dose; D1%, dose receiving ≥1% volume of CTV; D50%, dose receiving ≥50% volume of CTV; V1Gy, volume receiving ≥1 Gy of pre-
scribed dose; V3Gy, volume receiving ≥3 Gy of prescribed dose; NS, not statistically significant; LAD, left anterior descending coronary 
artery; CTV, clinical target volume.
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The dosimetric parameters according to tumor site were 
evaluated (Fig. 2). Dose distributions were perturbed by skin 
surface in EB plans, especially, at upper outer quadrant. CI of 
EB plans at upper outer quadrant showed the lowest among 
other quadrants. Moreover, EB plans have poor HI at all sites. 
Particularly, HI on upper inner and lower lateral quadrant are 
enhanced. In contrast, HT plans with directional and complete 
block of LAD were presented with better CI and HI regardless 
of sites. In cases of lower medial quadrant, 3DHT plans with 
directional block of LAD showed good coverage from QC.
2. Sparing OARs
Table 2 provides the numerical findings from the DVH analysis 
of the OARs. EB plans showed lower Dmean, D1% and V1Gy of skin 
compared to the 3DHT plans. Left lung and left breast also had 
the lowest Dmean in the EB plans. Although quality of the EB 
plans fluctuated among the patients and was affected by the 
target depth, EB plans showed superior OAR sparing, except 
LAD, than 3DHT plans with both directional block and complete 
block of LAD. On the other hand, 3DHT plans with complete 
block of LAD have understandably successful LAD sparing. 
3DHT plans with directional block of LAD showed overdose at 
LAD compared with EB in all cases. Low-dose volume of LAD 
was also increased in 3DHT with directional block in all cases 
(Table 3).
EB plans had no irradiated field at right lung and right 
breast. However, 3DHT plans, regardless of block type, showed 
low dose exposure in spite of less than 1 Gy of mean dose 
(Table 2). 3DHT plans with directional block of LAD showed 
mean dose of 0.25 ± 0.12 Gy of right lung and 0.30 ± 0.13 
Gy of right breast. 3DHT plans with complete block of LAD 
showed mean dose of 0.21 ± 0.10 Gy of right lung and 0.27 ± 
0.16 Gy of right breast. However, we found that there were no 
statistically significant differences among Dmean, D1%, and V3Gy 
to be compared with directional and complete block of LAD.
In terms of skin dose, the 3DHT plans increased the Dmean 
Table 3. Doses of left anterior descending artery according to quadrant of tumor site
Electron (E) HT-direction (D) HT-complete (C) p-value (ANOVA)
Subareolar
   Dmean (Gy)
   D1% (Gy)
   V1Gy (%)
   V3Gy (%)
Upper inner
   Dmean (Gy)
   D1% (Gy)
   V1Gy (%)
   V3Gy (%)
Upper outer
   Dmean (Gy)
   D1% (Gy)
   V1Gy (%)
   V3Gy (%)
Lower lateral
   Dmean (Gy)
   D1% (Gy)
   V1Gy (%)
   V3Gy (%)
Lower medial
   Dmean (Gy)
   D1% (Gy)
   V1Gy (%)
   V3Gy (%)
 
2.84 ± 0.82
5.83 ± 1.54
77.59 ± 5.41
42.66 ± 14.93
 
1.05 ± 0.70
2.95 ± 1.83
34.80 ± 25.55
12.77 ± 14.40
 
0.30 ± 0.14
0.91 ± 0.33
3.89 ± 3.14
0
 
0.81 ± 0.61
1.92 ± 1.53
30.03 ± 25.67
6.83 ± 9.66
 
3.43 ± 1.17
6.89 ± 1.54
75.09 ± 12.50
48.34 ± 18.69
 
2.61 ± 0.41
5.21 ± 1.58
85.17 ± 6.46
33.05 ± 12.98
 
1.75 ± 0.65
4.47 ± 1.77
67.82 ± 18.03
16.66 ± 14.06
 
0.64 ± 0.54
1.44 ± 0.88
30.73 ± 26.97
0
 
1.78 ± 0.77
2.59 ± 0.98
78.96 ± 15.30
15.09 ± 21.34
 
3.85 ± 0.80
6.48 ± 1.97
100
65.98 ± 6.58
 
0.63 ± 0.11
1.34 ± 0.31
10.51 ± 12.20
0
 
0.41 ± 0.10
1.14 ± 0.44
4.31 ± 5.78
0
 
0.20 ± 0.12
0.54 ± 0.29
0
0
 
0.48 ± 0.25
0.79 ± 0.40
4.94 ± 6.99
0
 
0.81 ± 0.10
1.89 ± 0.30
28.07 ± 13.03
0
 
E vs. D (0.04); E vs. C (<0.01); D vs. C (<0.01)
E vs. D (NS); E vs. C (0.01); D vs. C (0.01)
E vs. D (0.04); E vs. C (0.01); D vs. C (<0.01)
E vs. D (NS); E vs. C (<0.01); D vs. C (<0.01)
 
E vs. D (0.02); E vs. C (0.01); D vs. C (0.01)
E vs. D (0.01); E vs. C (0.01); D vs. C (0.01)
E vs. D (0.01); E vs. C (0.01); D vs. C (0.01)
E vs. D (NS); E vs. C (<0.01); D vs. C (<0.01)
 
E vs. D (NS); E vs. C (NS); D vs. C (NS)
E vs. D (NS); E vs. C (0.03); D vs. C (0.01)
E vs. D (<0.01); E vs. C (<0.01); D vs. C (<0.01)
-
 
E vs. D (0.01); E vs. C (0.02); D vs. C (0.03)
E vs. D (0.01); E vs. C (0.04); D vs. C (0.01)
E vs. D (<0.01); E vs. C (0.01); D vs. C (0.01)
E vs. D (<0.01); E vs. C (<0.01); D vs. C (<0.01)
 
E vs. D (NS); E vs. C (0.02); D vs. C (0.01)
E vs. D (NS); E vs. C (0.01); D vs. C (0.01)
E vs. D (0.03); E vs. C (0.01); D vs. C (0.01)
E vs. D (<0.01); E vs. C (<0.01); D vs. C (<0.01)
Values are presented as mean ± standard deviation.
HT-direction, helical tomotherapy with directional block of LAD; HT-complete, helical tomotherapy with complete block of LAD; Dmean, 
mean dose; D1%, dose receiving ≥1% volume of CTV; V1Gy, volume receiving ≥1 Gy of prescribed dose; V3Gy, volume receiving ≥3 Gy of 
prescribed dose; NS, not statistically significant; LAD, left anterior descending coronary artery; CTV, clinical target volume.
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and V1Gy in comparison to the EB plans. A similar trend was 
observed on the left lung and left breast. Although Dmean of 
lung was lower in EB plans, V3Gy representing the high-dose 
volume was higher than the 3DHT plans (Table 2). In contrast, 
the Dmean, D1%, and D50% of the left breast were higher in the 
3DHT plans than in the EB plans. In all plans, we found there 
was no more than 110% of the prescription dose.
We found that irradiated LAD volume was increased at 
subareolar, upper inner and lower medial quadrant due to 
anatomical direction of LAD. Particularly, in cases with tumor 
bed at lower medial quadrant, V1Gy of LAD was 100% (Fig. 2). 
LAD doses in all cases were extremely low in 3DHT plans with 
complete block of LAD. However, these plans showed increased 
irradiated dose of left breast (Fig. 3).
Discussion and Conclusion
We sought to evaluate dosimetric analysis of three different 
techniques for boost plans. We found that the 3DHT plans, 
regardless of block type of LAD, improved dose homogeneity 
compared with EB plans. 3DHT plans showed increased low-
dose volume of OARs in comparison with EB plans. In terms of 
LAD, 3DHT plans with complete block of LAD had significant 
LAD sparing from boost radiation, while they showed dose 
increase in left breast.
Although availability of 3DHT is proven by several studies 
[12,13], there is little evidence of usefulness of 3DHT for breast 
boost RT in our knowledge. In 3DHT, the gantry is continuously 
rotated around the patient with the multileaf collimator 
position calculated approximately every 7o or 51 times/rotation 
as the patient slowly moves longitudinally past the fan beam. 
3DHT can achieve highly conformal dose distribution at the 
cost of delivering a low dose of radiation to a large volume of 
coplanar normal tissues. Gantry angles can be directionally or 
completely blocked in the treatment-planning optimization to 
minimize entry and/or exit dose to OAR [14]. We adapted these 
blocks to minimize LAD dose.
In our study, 3DHT plans showed better target coverage 
compared with EB plans. In previous studies, photon beam 
plans showed superior target coverage than EB plans and 
3DHT plans were demonstrated better target coverage than 
photon beam plans. Park and Kim [15] reported that photon 
plans were superior to EB plans in terms of target coverage, 
even high-dose volume sparing in OAR for boost irradiation. 
And Goddu et al. [16] reported that tomotherapy IMRT plans 
provided better dose conformity and homogeneity than the 
three-dimensional plans for left-sided breast cancer. However, 
studies about dosimetric analysis of tomotherapy IMRT 
plans for breast cancer showed 107% to 114% of average 
hotspots [16,17]. Our study found that the average hotspots 
were 108% to 113% in 3DHT, while the other parameters of 
target coverage were favorable. Therefore, in terms of target 
coverage, 3DHT might be an alternative tool of tomotherapy 
IMRT. 
To find out difference in target coverage according to 
subsite, we separately analyzed the irradiated dose to tumor 
bed site. EB plans of all subsites showed poorer target 
coverage compared with 3DHT plans. Especially, EB plans of 
tumor beds at upper outer quadrant showed the lowest values 
of conformity because of thickness change inside the target 
volume and irregular surface of skin by axillary fold. The target 
coverage of EB plans might be influenced by thickness to 
6
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Fig. 3. Mean dose of LAD and left breast according to quadrant of tumor site. LAD, left anterior descending coronary artery; HT (D), 
helical tomotherapy with directional block of LAD; HT (C), helical tomotherapy with complete block of LAD.
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target and the irradiated surface. 
Oxford meta-analyses found increased risks of coronary 
heart disease for irradiated patients compared with non-
irradiated ones, or for patients treated to left breast compared 
to those treated to the right side [8,18,19]. Another report 
demonstrated that the rate of cardiovascular mortality 
increased in patients who received RT of inner-quadrants [20]. 
In our study, mean dose of LAD was higher at subareolar, 
upper inner, and lower medial quadrants compared with upper 
outer and lower lateral quadrants of tumor site in EB plans. 
EB plans of tumor beds at upper outer quadrant showed the 
lowest dose at LAD, probably because of the LAD anatomy. 
On the other hand, 3DHT plans with directional block of LAD 
showed higher mean dose of LAD in all subsites compared with 
EB plans. Moreover, 3DHT plans with directional block showed 
higher V1Gy and V3Gy of LAD at all quadrants of tumor site 
except subareolar. Although 3DHT plans with complete block 
of LAD showed the lowest dose of LAD in all subsites, these 
plans increased mean dose of left breast. Besides, right breast 
and right lung also had low dose radiation on 3DHT plans. 
The other report showed low dose exposure of breast 
increasing secondary breast cancer [21]. They demonstrated 
that women younger than 40 years who received more 
than 1 Gy of radiation dose to the contralateral breast had 
an elevated, long-term risk of developing a second primary 
contralateral breast cancer. In our study, mean dose of right 
breast was less than 1 Gy; 0.3 ± 0.13 Gy in 3DHT plans with 
directional block and 0.27 ± 0.16 in 3DHT plans with complete 
block. Although the clinical impact of additional low dose at 
contralateral breast is unclear for breast boost RT, the dose 
exposure for the right breast and lung was acceptable in 3DHT 
plans according dose limitations for normal tissues of RTOG 
[22].
3DHT plans, regardless of block type of LAD, had lower D50% 
of skin than EB plans (Table 2). In comparison with EB plans 
and photon beam plans in boost irradiation of breast cancer, 
the high-dose volume to the skin increased EB plans because 
of skin-sparing effect of photon [15]. However, we found that 
irradiated skin dose in 3DHT plans was increased compared 
with EB plans. In previous study, chest wall treatment plans 
from tomotherapy using by IMRT option showed higher skin 
dose than tangential delivery technique [23]. They explained 
the reasons for the higher skin dose are as follows: 1) the 
shallower dmax by slightly lower mean energy; 2) the shallow 
delivery angles; and 3) the smaller source-axis distance of 
the tomotherapy machine. These might be the causes of our 
findings.
In conclusion, 3DHT plans permitted more optimal target 
coverage than EB plans for boost RT in breast cancer patients. 
EB plans might be more preferred for OAR sparing except 
for LAD. 3DHT plans are preferable in upper outer quadrant 
of tumor beds for better target coverage. 3DHT plans with 
complete block of LAD might be considered in cases of 
subareolar, upper inner, lower lateral quadrants of tumor site 
to reduce the dose of LAD for breast cancer patients with 
cardiac morbidity.
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